Engineered CARD11–PIK3R3 T-cell therapies as weapons of cancer mass destruction

Abstract

Garcia et al. discover a novel immunotherapy approach by engineering naturally occurring mutations in therapeutic T cells to strongly elevate anti-tumor activity. The authors identify a gene fusion, CARD11–PIK3R3, to increase activator protein 1 and nuclear factor–κB signaling, interleukin-2 production, and tumor death in vitro and in vivo

.